Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 42% for any early termination, 30% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: equal toor equalgreater thansquamouscell
  Phrases that lowered it: upperlivernormalcountprostate
• Sponsor's past termination rate: 14.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 41.4% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 55 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 93.1% (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Keywords listed: 5 (lowers risk) · Design
• Drug's FAERS reports before start: 29 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 28 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cabazitaxel in Relapsed and Metastatic NSCLC NCT01852578 · started 2012 · scored riskier than 90% of active trials completed
• A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) NCT02166658 · started 2015 · scored riskier than 99% of active trials terminated
• Single Arm on the Tolerability of Weekly Nab-paclitaxel NCT01702844 · started 2013 · scored riskier than 98% of active trials completed
• Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer NCT02027428 · started 2014 · scored riskier than 58% of active trials completed
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer NCT00662597 · started 2008 · scored riskier than 77% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.